Acute Myelogenous Leukemia with Monosomy 7, inv(3) (q21q26), Involving Activated EVI 1 Gene Occurring after a Complete Remission of Lymphoblastic Lymphoma: A Case Report

Japanese Journal of Clinical Oncology

Volumn 28, Issue 11, 1998, Pages 688-695

  Igarashi, Tadahiko ^a   Shimizu, Seiichi ^b   Morishita, Kazuhiro ^b   Ohtsu, Tomoko ^a   Itoh, Kuniaki ^a   Minami, Hironobu ^a   Fujii, Hirofumi ^a   Sasaki, Yasutsuna ^a   Mukai, Kiyoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

EVI 1 gene; Inversion (3) (q21q26); Monosomy 7; Secondary acute myelogenous leukemia

Indexed keywords

DNA BINDING PROTEIN; EVI1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CASE REPORT; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME INVERSION; FEMALE; GENETICS; HUMAN; KARYOTYPING; LYMPHOBLASTOMA; MIDDLE AGED; MONOSOMY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROTO ONCOGENE; REMISSION; SECOND CANCER;

CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 7; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; FEMALE; HUMANS; INVERSION, CHROMOSOME; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA, LYMPHOBLASTIC; MIDDLE AGED; MONOSOMY; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENES; REMISSION INDUCTION; TRANSCRIPTION FACTORS;

EID: 0032214243     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.11.688     Document Type: Article

References (43)

1. Tucker MA, Meadows AT, Boice JD Jr, Stovall M, Oberlin O, Stone BJ, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78:459-64.
2. Tucker MA, Coleman CN, Cox RS, Varghese A. Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988;318:76-81.
3. Cimino G, Papa G, Tura S, Mazza P, Rossi Ferrini PL, Bosi A. et al. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol 1991;9:432-7.
4. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326:1745-51.
5. Kreissman SG, Gelber RD, Cohen HJ, Clavell LA, Leavitt P, Sallan SE. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer 1992;70:2208-13.
6. Parker RG. Radiation-induced cancer as a factor in clinical decision making. Int J Radiat Oncol Biol Phys 1990;18:993-1000.
7. Andrieu JM, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990;8:1148-54.
8. Lavey RS, Eby ML, Prosnitz LR. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 1990;66:80-8.
9. Pederson-Bjergaard J, Ersbøll J, Sørensen MH, Keiding N, Larsen SO, Philip P, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med 1985;103:195-200.
10. van Leeuwen FE, Somers R, Taal BG, van Heerde P, Coster B, Dozeman T, et al. Increased risk of lung cancer, non-Hodgkin's lymphoma and leukemia following Hodgkin's disease. J Clin Oncol 1989;7:1046-58.
11. Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute leukemia. Leukemia Res 1992;16:61-5.
12. Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993;11:209-17.
13. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994;12:2535-42.
14. Damngton DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC. et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994;12:2527-34.
15. Pederson-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy related acute myeloid leukemia. Blood 1995;86:3542-52.
16. Smith MA, McCaffrey RP, Karp JE The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996;88:407-18.
17. Whang-Peng J, Young RC, Lee EC, Longo DL, Schechter GP, De Vita VT Jr. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988;71:403-14.
18. Pedersen-Bjergaard J, Rowley J. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation Blood 1994;83:2780-6.
19. Bitter MA, Neilly ME, Le Beau MM, Pearson MG, Rowley JD. Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia. Blood 1985;66:1362-70.
20. Jenkins RB, Teffen A, Solberg LA, Dewald GW. Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. Cancer Genet Cytogenet 1989;39:167-79.
21. Gardais J, Baranger L. Inversion of chromosome 3 (q21;q26) in a case of secondary acute leukaemia with thrombocythaemia (letter). Leukemia Res 1992;16:547-8.
22. Fichelson S, Dreyfus F, Berger R, Melle J, Bastard C, Miclea JM. et al. Evi-1 expression in leukemic patients with rearrangements of the 3q25-q28 chromosomal region. Leukemia 1992;6:93-9.
23. Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K, et al. Identification of a breakpoint cluster region 3′ of the ribophorin 1 gene at 3q21 associated with the transcriptional activation of the EVI 1 gene in acute myelogenous leukemias with inv (3) (q21q26). Blood 1994;84:2681-8.
24. Bellomo MJ, Parlier V, Muhlematter D, Grob JP, Beris P. Three new cases of chromosome 3 rearrangements in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q213q26 syndrome. Cancer Genet Cytogenet 1992;59:138-60
25. Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig WD, et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3) (q21q26) ort(3;3) (q21 ;q26). Leukemia 1994;8:1318-26.
26. Levy ER, Parganas E, Morishita K, Fichelson S, James L, Oscier D. et al. DNA rearrangements proximal to the EVI 1 locus associated with the 3q21q26 syndrome. Blood 1994;83:1348-54.
27. Morishita K, Parganas E, Willman CL, Whittaker MH, Drabkin H, Oval J, et al Activation of EVI 1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome 3q26. Proc Natl Acad Sci USA 1992;89:3937-41.
28. Morishita K, Parganas E, Parham DM, Matsugi T. Ihle JN. The Evi-I zinc finger myeloid transforming gene is normally expressed in the kidney and in developing oocytes. Oncogene 1990;5:1419-23.
29. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia A report of the French-American-British Group. Ann Intern Med 1985;103:620-5.
30. ISCN. Guidelines for cancer cytogenetics In: Mitelman F, editor. Supplement to an International System for Human Cytogenetic Nomenclature. Basel: Karger, 1991.
31. Oval J, Smedsrud M, Taetle R. Expression and regulation of the Evi-I gene in the human factor-dependent leukemia cell line, UCSD/AMLI. Leukemia 1992;6:446-51.
32. Asou H, Eguchi M, Suzukawa K, Morishita K, Tanaka K, Date M. et al. Establishment of a myeloid leukemia cell line (Kasumi-4) with t(9;22;11) (q34:q11;q13), inv(3) (q21q26) and the EVI 1 gene activation from a patient with chronic myelogenous leukaemia in blastic crisis. Br J Haematol 1996;93:68-74.
33. McKeithan TW, Shima EA, Le Beau MM, Minowada J, Rowley JD, Diaz MO. Molecular cloning of the breakpoint junction of a human chromosomal 8:14 translocation involving the T-cell receptor α-chain gene and sequences on the 3′ side of MYC. Proc Natl Acad Sci USA 1986;83:6636-40.
34. Suzukawa K, Taki T, Abe T, Asoh, Kamada N, Yokota J. et al. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI 1 gene in two cases of CML-BC with inv(3) (q21q26). Genomics 1997;42:356-60.
35. Inhom RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R, et al. A syndrome of lymphoblastic lymphoma, eosinophilia and myeloid hyperplasia/malignancy associated with t(8;13) (p11.q11): description of a distinctive clinicopathologic entity. Blood 1995;85;1881-7.
36. Abruzzo LV, Jaffe ES, Cotelmgam JD, Whang-Peng J, Duca VD Jr. Medeiros J. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol 1992;16:236-45.
37. Launder TM, Bray RA, Stempora L, Chenggis ML. Farhi DC Lymphoid-associated antigen expression by acute myeloid leukemia. Am J Clin Pathol 1996;106:185-91.
38. Greene MH, Young RC, Merrill JM, DeVita VT Jr. Evidence of dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983;43:1891-8.
39. Travis LB, Curtis RE, Boice JD Jr, Hankey BF. Fraumeri JF Jr. Second cancers following non-Hodgkin's lymphoma. Cancer 1991;67:2002-9.
40. Hoelzer D, Thiel E, Loffler H, Bodenstein H, Plaumann L, Bückner T. et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984;64:38-47.
41. Slater DE, Mertelsmann R, Kazmer B, Higgins C, McKenzie S, Schauer P, et al. Lymphoblastic lymphoma in adults J Clin Oncol 1986;4:57-67.
42. Wang JC. DNA topoisomerase. Annu Rev Biochem 1996;65:635-92.
43. Neugut AI, Robinson E, Nieves J, Murray T, Tsai WY. Poor survival of treatment-related acute nonlymphocytic leukemia. J Am Med Assoc 1990;264:1006-8.